WallStreetZen

NYSE: LLY
ELI LILLY & Co Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

LLY past earnings growth

How has LLY's earnings growth performed historically?
Company
6.83%
Industry
22.33%
Market
96.23%
LLY's earnings have grown faster (23.14% per year) than the US Drug Manufacturers - General industry average (11.67%)
Performance
LLY's earnings have grown slower (23.14% per year) than the US market average (33.21%)
Performance
LLY's earnings growth is slowing down - its growth over the last year (6.83%) is below its 5-year compound annual rate (23.14%)
Performance

LLY past revenue growth

How has LLY's revenue growth performed historically?
Company
19.58%
Industry
18.11%
Market
42.59%
LLY's revenue has grown faster (5.9% per year) than the US Drug Manufacturers - General industry average (5.44%)
Performance
LLY's revenue has grown slower (5.9% per year) than the US market average (19.59%)
Performance
LLY's revenue growth is accelerating - its growth over the last year (19.58%) is above its 5-year compound annual rate (5.9%)
Performance

LLY earnings and revenue history

Current Revenue
$27.8B
Current Earnings
$6.0B
Current Profit Margin
21.5%
LLY's has not demonstrated consistent long-term earnings growth over the past 10 years (57.18%)
Performance

LLY Return on equity

Current Company
89.3%
Current Industry
50.7%
Current Market
21.6%
LLY's Return on Equity (89.3%) shows a company that is highly efficient at transforming shareholder equity into returns
Performance

LLY Return on assets

Current Company
12.6%
Current Industry
8.3%
LLY is generating higher Return on Assets (12.6%) than the US Drug Manufacturers - General industry average (7.57%)
Performance

LLY Return on capital employed

Current Company
19.66%
Current Industry
12.5%
LLY has gotten more efficient at generating Return on Capital (19.66%) compared to 3 years ago (9.17%)
Performance

ELI LILLY & Earnings & Revenue FAQ

What were LLY's earnings last quarter?

On Invalid Date, ELI LILLY & (NYSE: LLY) reported Q3 2021 earnings per share (EPS) of $1.22, up 8.27% year over year. Total ELI LILLY & earnings for the quarter were $1.11 billion. In the same quarter last year, ELI LILLY &'s earnings per share (EPS) was $1.33.

What was LLY's earnings growth in the past year?

As of Q4 2021, ELI LILLY &'s earnings has grown 6.83% year over year. This is 15.5 percentage points lower than the US Drug Manufacturers - General industry earnings growth rate of 22.33%. ELI LILLY &'s earnings in the past year totalled $5.97 billion.

What was LLY's revenue last quarter?

On Invalid Date, ELI LILLY & (NYSE: LLY) reported Q3 2021 revenue of $6.77 billion up 17.98% year over year. In the same quarter last year, ELI LILLY &'s revenue was $5.74 billion.

What was LLY's revenue growth in the past year?

As of Q4 2021, ELI LILLY &'s revenue has grown 19.58% year over year. This is 1.47 percentage points higher than the US Drug Manufacturers - General industry revenue growth rate of 18.11%. ELI LILLY &'s revenue in the past year totalled $27.76 billion.
©2021 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatisticsTrending Stocks
Analysts
Top Performing Analysts
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.